Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model
Authors:
- Concettina La MottaConcettina La Motta
- Stefania SartiniSSStefania Sartini
- Silvia SalernoSSSilvia Salerno
- Francesca SimoriniFSFrancesca Simorini
- Sabrina TalianiSTSabrina Taliani
- Anna Maria MariniAMAnna Maria Marini
- Federico Da SettimoFSFederico Da Settimo
- Luciana MarinelliLuciana Marinelli
- Vittorio LimongelliVLVittorio Limongelli
- Ettore NovellinoENEttore Novellino
- 2 May 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (11) , 3182-3193
Abstract
A number of 1,2,4-oxadiazol-5-yl-acetic acids and oxazol-4-yl-acetic acids were synthesized and tested for their ability to inhibit aldose reductase (ALR2). The oxadiazole derivatives, 7c, 7f, 7i, and 8h, 8i, proved to be the most active compounds, exhibiting inhibitory levels in the submicromolar range. In this series, the phenyl group turned out to be the preferred substitution pattern, as its lengthening to a benzyl moiety determined a general reduction of the inhibitory potency. The lead compound, 2-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]acetic acid, 7c, showed an excellent in vivo activity, proving to prevent cataract development in severely galactosemic rats when administered as an eye-drop solution in the precorneal region of the animals. Computational studies on the ALR2 inhibitors were performed to rationalize the structure−activity relationships observed and to provide the basis for further structure-guided design of novel ALR2 inhibitors.Keywords
This publication has 44 references indexed in Scilit:
- A central role for inflammation in the pathogenesis of diabetic retinopathyThe FASEB Journal, 2004
- Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic NeuropathyDiabetes, 2004
- The Pharmacology of Diabetic ComplicationsCurrent Medicinal Chemistry, 2003
- Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic ComplicationsCurrent Medicinal Chemistry, 2003
- Aldose Reductase Inhibitors from the NatureCurrent Medicinal Chemistry, 2003
- Genetic Analysis of Aldose Reductase in Diabetic ComplicationsCurrent Medicinal Chemistry, 2003
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- A role for mitogen‐activated protein kinases in the etiology of diabetic neuropathyThe FASEB Journal, 2001
- Hyperglycemic Pseudohypoxia and Diabetic ComplicationsDiabetes, 1993
- The role of aldose reductase in the development of diabetic complicationsMedicinal Research Reviews, 1988